Seegene Unveils STAgora™: A New Era in Infectious Disease Analytics

Seegene Unveils Revolutionary STAgora™ for Infectious Disease Analysis



In a groundbreaking announcement, Seegene Inc., a leader in molecular diagnostics, has launched a next-generation platform known as STAgora™. This innovative system is designed to provide real-time insights into infectious disease analytics, fundamentally transforming the way health professionals monitor and respond to disease outbreaks globally.

A Real-Time Solution for Emerging Infectious Threats



The STAgora™ platform enables the visualization of outbreak data in real-time across multiple geographical levels, including municipal, national, and continental scopes. Using actual diagnostic test results, the platform equips healthcare professionals with immediate access to structured diagnostic reports and statistical analyses presented in user-friendly formats.

Customized dashboards and real-time alert functions ensure that users can promptly track individual cases and regional outbreaks. Such capabilities significantly enhance situational awareness, allowing for timely, data-driven public health responses. The platform aims to deliver epidemiological analytics in real-time to national and global health authorities, strengthening decision-making processes and developing effective responses to mitigate large-scale infectious disease outbreaks.

With over 40 built-in statistical tools, STAgora™ can identify abnormal pathogen spread patterns early on. It supports predictive modeling of seasonal trends and emerging disease outbreaks. Its tools include modules for tracking specific infections, analyzing co-infections based on symptoms, and calculating real-time morbidity trends—which altogether facilitate the transition from static data to forward-looking analytics that guide proactive interventions.

Redefining Disease Monitoring with Advanced Technology



Unlike traditional disease outbreak monitoring systems that rely on retrospective data, STAgora™ performs real-time PCR diagnostic analysis. This real-time capability enables immediate tracking of pathogen spread and uses AI-based algorithms to forecast potential future outbreaks.

Young-Seag Baeg, Chief Strategic Plans Officer at Seegene, stated, “The primary distinction of STAgora™ lies in its unique architecture, which aggregates real-time diagnostic data from across the globe into a singular analytical platform. Combined with Seegene’s proprietary syndrome quantitative PCR technology, STAgora™ provides an enhanced visualization of data regarding single-pathogen infections and simultaneous multi-pathogen infections.”

This comprehensive diagnostic information empowers clinicians to make quicker, more informed decisions at points of care.

A Timely Launch for Global Health Needs



Daniel Shin, Seegene’s Executive Vice President and Global Sales and Marketing Director, emphasized the platform's relevance, stating, “During the COVID-19 pandemic, we witnessed how critical timely and accurate interpretation of diagnostic data is for public health policies and clinical outcomes. Today, facing increasingly sophisticated threats like antimicrobial resistance, viral mutations, and co-infections, our ability to deliver actionable analytics based on diagnostic data is paramount to clinical innovations and a vital pillar of global health security.”

The official unveiling of STAgora™ will take place at the upcoming annual meeting of the Association for Diagnostics and Laboratory Medicine (ADLM) 2025, scheduled for July 27-31 in Chicago, USA. This event will showcase the platform's capabilities, including its integration with Seegene's fully automated PCR system, CURECA™. Moreover, it will serve as a venue for exploring global collaborations and partnerships with health leaders and clients.

With the introduction of STAgora™, Seegene aims to lay the groundwork for a smarter, faster, and interconnected global health system. By combining real-time molecular diagnostics, AI-driven analytics, and global data integration, STAgora™ signifies a strategic advancement towards establishing an intelligent healthcare infrastructure capable of proactively responding to emerging threats.

Seegene’s Journey and Innovations



Seegene brings 20 years of experience in R&D and business focused on the syndrome approach to real-time PCR testing. This expertise was crucial during the COVID-19 pandemic, as the company supplied over 340 million COVID-19 tests to more than 100 countries worldwide. One significant aspect of Seegene's real-time syndrome diagnostics is the ability to simultaneously test 14 pathogens causing similar symptoms in a single sample, yielding quantitative results.

About CURECA™



CURECA™ (Continuous, Unlimited, Random-access, Extendable, Customizable Automation) is Seegene's fully automated modular PCR system that eliminates manual processes, allowing for continuous real-time testing. This unified platform is designed for round-the-clock operation without human intervention. The first component, CPS, is the world's first automated pre-processing system capable of handling a wide range of sample types, including blood, stool, sputum, and urine. CURECA™ offers scalable automation and flexible deployment, making it invaluable in space- or personnel-limited setups.

For more information, visit Seegene.com and follow us on LinkedIn.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.